Element Biosciences vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Element Biosciences makes the AVITI benchtop DNA sequencer; raised $277M Series D in 2024 (led by Wellington Management, Samsung) for $680M+ cumulative; install base grew from ~40 to 190+ units in 12 months.
About
Element Biosciences is a genomics company developing next-generation DNA sequencing instruments and reagents designed to democratize access to high-quality, cost-effective sequencing. Founded in 2017 by veterans from Illumina, Life Technologies, and other genomics leaders, the company is headquartered in San Diego, California. Its flagship product, the AVITI System, is a benchtop sequencer that combines high accuracy, flexible throughput, and competitive per-sample costs — making research-grade sequencing accessible to academic labs, biotech companies, agricultural research programs, and clinical settings that previously could not justify large capital outlays for sequencing infrastructure.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Element Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.